NorthWest Biotherapeutics Inc (NWBO)

[Nemesis18]

One of the highlighted published concerns about this trial was the selection of patients, who, due to their favourable histology, resection %, genomic profile, age, tumour siting, performance status etc, had been selected over those with less promising prognosticators.
With those patients having an extended OS with or without the ‘vaccine’.
Moreover, Those with helpful MGMT status, showed a significant reduction in OS for having the vaccine. The latest European study showed that a very large % of this group had a life expectancy of 9.9 years.

Further, where is the reporting of IDH status. Another important prognosticator in the reclassification of CNS tumours.

For these and many other reasons, the Neuro Scientific community have stated that the clinical trial data is utterly un interpretable now.

As the trial took > 10years, the world & scientific understanding of Glioblastoma has moved on.